Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02107976 · ClinicalTrials.gov registry record · Phase 1

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

A Phase 1 study of Diabetes Type 2, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Completed
Registry status
Phase 1
Development phase
55
Enrollment target
1
Study location

NCT02107976: Completed Phase 1 study of Diabetes Type 2, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

NCT02107976 is a Phase 1 study of Diabetes Type 2 that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 55 participants, below the 665-participant average among 24 other Diabetes Type 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02107976, a Phase 1 study of Diabetes Type 2, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

COMPLETED
Registry status
Phase 1
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

Diabetes type two is a debilitating disease that leads to chronic morbidity such as accelerated microvascular disease. Accelerated microvascular disease may produce blindness, end stage renal disease, myocardial infarction, stroke, and limb ischemia. Strategies to prevent or delay microvascular disease have the potential to improve the lives of millions and prevent catastrophic illness. The major focus of prevention of microvascular disease in diabetes has been on the endothelium and its role in protection of blood vessels. An unexpected means to prevent microvascular disease in diabetes may be coupled to the function of vitamin C in red blood cells (RBCs) of diabetic subjects. Based on new and emerging data, vitamin C concentrations in RBCs may be inversely related to glucose concentrations found in diabetes. Based on animal data, we hypothesize that RBCs with low vitamin C levels may have decreased deformability, leading to slower flow in capillaries and microvascular hypoxia, the hallmark of diabetic microangiopathy. Low vitamin C concentrations in RBCs of diabetic subjects may be able to be increased, by using vitamin C supplements. Findings in animals may not accurately reflect effects in humans because of species differences in mechanisms of vitamin C entry into RBCs. Therefore, clinical research is essential to characterize vitamin C physiology in RBCs of diabetic subjects. In this protocol we will investigate physiology of vitamin C in RBCs of diabetic subjects as a function of glycemia, without vitamin C supplementation (stage 1) and with vitamin C supplementation (stage 2). We will screen type II diabetic subjects on insulin and/or oral hypoglycemic medication(s) and select those with hemoglobin A1C concentrations of less than or equal to 12%. Selected subjects may be hospitalized twice, each time for approximately one week. The primary objective of the first hospitalization (stage 1) will be to evaluate the effect of hyperglycemia on vitamin C RBC physiol

Primary Outcome

Difference in mean AUC for RBC deformability half maximal shear stress (SS0.5) from baseline to the 8-week follow-up visit, using controlled hyperglycemia conditions (glucose 200-400 mg/dL). The insulin regimen will be withheld to produce controlled hyperglycemia \< 400 mg/dl. Subjects were provided a high carbohydrate diet (70-75% carbohydrate) on the day of hyperglycemia. During the hyperglycemic condition, blood samples will be drawn every one to two hours for RBC deformability measurements,

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Vitamin C
  • DIETARY_SUPPLEMENT Vitamin E

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2019-06-14
Est. Completion 2025-03-05
Phase Phase 1

What the finished NCT02107976 record still lists

NCT02107976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 665-participant average among 24 other Diabetes Type 2 trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Diabetes Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Vitamin C is the first listed.

NCT02107976 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02107976 about?

NCT02107976 is a clinical study titled "Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes". Diabetes type two is a debilitating disease that leads to chronic morbidity such as accelerated microvascular disease. Accelerated microvascular disease may produce blindness, end stage renal disease, myocardial infarction, stroke, and limb ischemia. Strategies to prevent or delay microvascular dise...

What is the current status of trial NCT02107976?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2019-06-14. Estimated completion is 2025-03-05.

What conditions does trial NCT02107976 study?

This clinical trial studies the following conditions: Diabetes Type 2.

What interventions are being tested in trial NCT02107976?

The interventions under investigation include: Vitamin C (DIETARY_SUPPLEMENT), Vitamin E (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02107976?

This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02107976 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02107976's enrollment target sits among peer trials

55 23rd of 24 higher than 2 of 24 other Diabetes Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02107976, the US trial registry maintained by the National Library of Medicine. NCT02107976 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.